In a research report issued Thursday, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on shares of Neuralstem, Inc. (NASDAQ:CUR), with an $8.00 price target, after the biotech company announced additional in vitro data on NSI-189, a neurogenic compound enhances short-term and long-term potentiation in C57Bl/6 mice and reverses LTP impairment in a mouse model of Angelman syndrome.
Aschoff wrote, “NSI-189 showed enhancement of both short-term potentiation (STP) and long-term potentiation (LTP) in C57BI/6 mice and restored LTP in Angelman syndrome mice. LTP is an important biomarker of memory, and we believe that these preclinical data provide a cellular explanation for the long duration of efficacy (Day 28 to Day 84) observed in the NSI-189 Phase 1b trial. The novel cognitive mechanism of NSI-189, along with its rapid onset of action and durability of effect has the potential to treat MDD, although this result must be replicated in larger trials. Neuralstem initiated a 220-patient multi-site Phase 2 trial in 2Q16 with NSI-189 for MDD. We look forward to the release of results in 2H17.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jonathan Aschoff has a yearly average return of -13% and a 31% success rate. Aschoff has a -70.5% average return when recommending CUR, and is ranked #3871 out of 3980 analysts.
As of this writing, all the 2 analysts polled by TipRanks rate Neuralstem stock a Buy. With a huge return potential of 2233%, the stock’s consensus target price stands at $7.